KR20230046711A - COMPOSITION FOR PROMOTING BIOFILM FORMATION COMPRISING EXTRACT OF Polygonati Rhizoma - Google Patents
COMPOSITION FOR PROMOTING BIOFILM FORMATION COMPRISING EXTRACT OF Polygonati Rhizoma Download PDFInfo
- Publication number
- KR20230046711A KR20230046711A KR1020210130032A KR20210130032A KR20230046711A KR 20230046711 A KR20230046711 A KR 20230046711A KR 1020210130032 A KR1020210130032 A KR 1020210130032A KR 20210130032 A KR20210130032 A KR 20210130032A KR 20230046711 A KR20230046711 A KR 20230046711A
- Authority
- KR
- South Korea
- Prior art keywords
- streptococcus
- extract
- composition
- biofilm formation
- hwangjeong
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 36
- 230000032770 biofilm formation Effects 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 230000001737 promoting effect Effects 0.000 title claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 241000894006 Bacteria Species 0.000 claims description 29
- 244000005700 microbiome Species 0.000 claims description 11
- 241000605862 Porphyromonas gingivalis Species 0.000 claims description 10
- 241001135221 Prevotella intermedia Species 0.000 claims description 8
- 241000194017 Streptococcus Species 0.000 claims description 8
- 241000194019 Streptococcus mutans Species 0.000 claims description 8
- 241000194024 Streptococcus salivarius Species 0.000 claims description 8
- 241000193987 Streptococcus sobrinus Species 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 241000589996 Campylobacter rectus Species 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 241000605986 Fusobacterium nucleatum Species 0.000 claims description 6
- 241000589892 Treponema denticola Species 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 claims description 5
- 241001135235 Tannerella forsythia Species 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- 241000588878 Eikenella corrodens Species 0.000 claims description 4
- 241001464887 Parvimonas micra Species 0.000 claims description 4
- 241001135225 Prevotella nigrescens Species 0.000 claims description 4
- 241001494431 [Eubacterium] nodatum Species 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- 241000589886 Treponema Species 0.000 claims 1
- 238000011161 development Methods 0.000 abstract description 4
- 241001148471 unidentified anaerobic bacterium Species 0.000 abstract description 4
- 208000025157 Oral disease Diseases 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 208000030194 mouth disease Diseases 0.000 abstract description 2
- 239000013588 oral product Substances 0.000 abstract description 2
- 241000756042 Polygonatum Species 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000012258 culturing Methods 0.000 description 15
- 238000000605 extraction Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 5
- 229910017053 inorganic salt Inorganic materials 0.000 description 5
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 4
- 239000007621 bhi medium Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229910052719 titanium Inorganic materials 0.000 description 4
- 239000010936 titanium Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 2
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 2
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 2
- 229940093496 esculin Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014666 Endocarditis bacterial Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000037831 Polygonatum sibiricum Species 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000009361 bacterial endocarditis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 황정 추출물을 포함하는 바이오필름 형성 촉진용 조성물에 관한 것이다.The present invention relates to a composition for accelerating biofilm formation comprising a hwangjeong extract.
바이오필름(biofilm)은 생물막이라고도 불리며, 미생물이 세포 주위에 다당체를 생산하고 이것을 매개로 인접한 미생물과 응집하여 고체나 생체 표면에 막(film)을 형성하고 있는 상태를 의미한다.A biofilm, also called a biofilm, refers to a state in which microorganisms produce polysaccharides around cells and aggregate with adjacent microorganisms through the medium to form a film on a solid or biological surface.
바이오필름은 치아 우식증, 세균성 심내막염, 만성 부비동염, 식중독, 폐렴 등과 같이 여러 질병의 발병(pathogenesis)에 중요한 역할을 하는 것으로 알려져 있으며, 포르피로모나스 진지발리스(Porphyromonas gingivalis)로 대표되는 구강 세균에 의해 주로 형성된다.Biofilm is known to play an important role in the pathogenesis of various diseases such as dental caries, bacterial endocarditis, chronic sinusitis, food poisoning, pneumonia, etc., and by oral bacteria represented by Porphyromonas gingivalis mainly formed
그러나, 이러한 구강 세균은 일반적으로 혐기성(anaerobic) 세균으로 특정 조건에서만 배양되기 때문에, 이를 이용한 실험 설계가 매우 까다롭고 전문가의 노하우가 많이 필요하여, 세균이 충분히 번식하는 데 비용과 시간이 많이 소요되는 문제가 있다.However, since these oral bacteria are generally anaerobic bacteria and are cultured only under specific conditions, the experimental design using them is very difficult and requires a lot of expert know-how, which is costly and time-consuming for bacteria to sufficiently propagate. there is a problem.
이러한 이유로 실험실 수준에서 혐기성 세균(바이오필름)의 형성을 촉진하는 천연물 유래 물질의 개발은 필수적이며 계속적인 연구가 필요한 상태이다.For this reason, the development of a natural product-derived material that promotes the formation of anaerobic bacteria (biofilm) at the laboratory level is essential and requires continuous research.
본 발명자들은 부작용이 적은 천연물 유래 바이오필름 형성 촉진제를 개발하고자 예의 연구 노력하였다. 그 결과, 황정(Polygonati Rhizoma)이 바이오필름 형성을 촉진하는 능력이 우수한 것을 확인함으로써, 본 발명을 완성하였다.The present inventors have intensively researched to develop a natural product-derived biofilm formation promoter with fewer side effects. As a result, the present invention was completed by confirming that Polygonati Rhizoma has an excellent ability to promote biofilm formation.
따라서, 본 발명의 목적은 황정(Polygonati Rhizoma) 추출물을 유효성분으로 포함하는 바이오필름 형성 촉진용 조성물을 제공하는 것이다.Accordingly, an object of the present invention is to provide a composition for promoting biofilm formation comprising Polygonati Rhizoma extract as an active ingredient.
본 발명의 다른 목적은 황정 추출물을 유효성분으로 포함하는 구강 세균 배양용 조성물을 제공하는 것이다.Another object of the present invention is to provide a composition for culturing oral bacteria comprising a hwangjeong extract as an active ingredient.
본 발명자들은 부작용이 적은 천연물 유래 바이오필름 형성 촉진제를 개발하고자 예의 연구 노력하였다. 그 결과, 황정(Polygonati Rhizoma)이 바이오필름 형성을 촉진하는 능력이 우수한 것을 확인하였다.The present inventors have intensively researched to develop a natural product-derived biofilm formation promoter with fewer side effects. As a result, it was confirmed that Hwangjeong ( Polygonati Rhizoma ) has an excellent ability to promote biofilm formation.
본 발명은 황정 추출물을 유효성분으로 포함하는 바이오필름 형성 촉진용 조성물 및 구강 세균 배양용 조성물에 관한 것이다.The present invention relates to a composition for promoting biofilm formation and a composition for culturing oral bacteria, comprising an extract of Hwangjeong as an active ingredient.
본 발명은 황정(Polygonati Rhizoma) 추출물을 이용하여 티타늄 표면에서 바이오필름의 형성 촉진 효능에 있어서 유의미한 결과를 확인하였다.The present invention confirmed a significant result in the biofilm formation promoting effect on the titanium surface using the Hwangjeong ( Polygonati Rhizoma ) extract.
이하, 본 발명을 더욱 자세히 설명하고자 한다.Hereinafter, the present invention will be described in more detail.
본 발명의 일 양태에 따르면, 본 발명은 황정(Polygonati Rhizoma) 추출물을 유효성분으로 포함하는 바이오필름 형성 촉진용 조성물에 관한 것이다.According to one aspect of the present invention, the present invention relates to a composition for promoting biofilm formation comprising Polygonati Rhizoma extract as an active ingredient.
본 발명에서, "황정(Polygonati Rhizoma)"은 백합과 식물인 낚시둥굴레(Polygonatum sibiricum Rehd.)의 뿌리줄기를 말린 것으로, 혈압강하 작용, 혈당량강하 작용, 항동맥경화 작용, 간지방 침착방지 작용 등을 가진 것으로 알려져 있다.In the present invention, "Hwangjeong ( Polygonati Rhizoma )" is a dried rhizome of Polygonatum sibiricum Rehd., a plant of the lily family, and has blood pressure lowering action, blood sugar lowering action, anti-arteriosclerosis action, liver fat deposition prevention action, etc. is known to have
본 명세서에서 사용되는 용어 '추출물'은 당업계에서 조추출물(crude extract)로 통용되는 의미를 갖지만, 광의적으로는 추출물을 추가적으로 분획(fractionation)한 분획물도 포함한다. 즉, 황정 추출물은 상술한 추출 용매를 이용하여 얻은 것뿐만 아니라, 여기에 정제과정을 추가적으로 적용하여 얻은 것도 포함한다. 예컨대, 상기 추출물을 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 얻은 분획, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 황정 추출물에 포함되는 것이다.The term 'extract' used herein has a meaning commonly used in the art as a crude extract, but also includes a fraction obtained by further fractionating the extract in a broad sense. That is, Hwangjeong extract includes not only those obtained using the above-described extraction solvent, but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the extract through an ultrafiltration membrane having a certain molecular weight cut-off value, separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity), etc. The fraction obtained through the purification method is also included in the Hwangjeong extract of the present invention.
본 발명의 황정 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.The Hwangjeong extract of the present invention may be prepared in a powder state by additional processes such as distillation under reduced pressure and freeze drying or spray drying.
본 발명에서, 추출 용매는 물, 및 탄소수 1 내지 4개의 직쇄 또는 분지형 알코올, 아세톤, 에틸아세테이트, 부틸아세테이트, 1,3-부틸렌 글리콜, 헥산 및 디에틸에테르로 이루어진 군에서 선택된 1종 이상의 용매인 것일 수 있으나, 이에 한정되는 것은 아니다. In the present invention, the extraction solvent is at least one selected from the group consisting of water, straight chain or branched alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, butyl acetate, 1,3-butylene glycol, hexane and diethyl ether It may be a solvent, but is not limited thereto.
본 발명에서, 추출 온도는 예를 들어 0 ℃ 내지 150 ℃일 수 있으며, 구체적으로는 50 ℃ 내지 100 ℃일 수 있으나, 이에 한정되는 것은 아니다.In the present invention, the extraction temperature may be, for example, 0 °C to 150 °C, specifically 50 °C to 100 °C, but is not limited thereto.
본 발명에서, 추출 시간은 예를 들어 1시간 내지 10 시간일 수 있으며, 구체적으로는 3 시간 내지 8시간일 수 있고, 더욱 구체적으로는 5 시간 내지 7 시간일 수 있으나, 이에 한정되는 것은 아니다.In the present invention, the extraction time may be, for example, 1 hour to 10 hours, specifically 3 hours to 8 hours, and more specifically 5 hours to 7 hours, but is not limited thereto.
본 발명의 황정 추출물은 공지의 천연물 추출법으로 추출될 수 있다. 예를 들어 냉침 추출, 열수 추출, 초음파 추출, 환류냉각 추출, 가열 추출법으로 추출할 수 있으며, 구체적으로는 열수 추출 또는 환류 냉각 추출법으로 추출할 수 있으며, 1회 내지 10회, 보다 구체적으로는 2회 내지 7회 반복 추출할 수 있다.Hwangjeong extract of the present invention can be extracted by a known natural product extraction method. For example, it can be extracted by cold extraction, hot water extraction, ultrasonic extraction, reflux cooling extraction, and heating extraction. Specifically, it can be extracted by hot water extraction or reflux cooling extraction, 1 to 10 times, more specifically 2 Extraction can be repeated 7 times to 7 times.
본 발명에서, 상기 바이오필름 형성 촉진용 조성물은 상기 황정 추출물을 1 mg/mL의 농도로 포함할 수 있다.In the present invention, the composition for promoting biofilm formation may include the Hwangjeong extract at a concentration of 1 mg/mL.
본 발명에서, "바이오필름(biofilm)"은 미생물이 표면에 축척하여 세포와 결합되어 있는 다량의 고분자 화합물과 표면에 부착되는 유기물, 무기물로 이루어진 얇은 막을 의미하며, 생물막과 상호 교환적으로 사용될 수 있다. 바이오필름 내의 세균은 부유상태보다 항생물질에 대한 내성이 10 배 내지 1000배 이상 증가될 수 있으며, 세균의 형질이 변해서 세포외 다당물질이나 산소에 의해 항생물질이 불활성화 되거나, 바이오필름 형성으로 인해 성장속도를 늦추어 내성을 획득하게 된다.In the present invention, "biofilm" refers to a thin film composed of a large amount of macromolecular compounds in which microorganisms accumulate on the surface and are associated with cells, and organic substances and inorganic substances attached to the surface, and can be used interchangeably with biofilms. there is. Bacteria in biofilms can increase their resistance to antibiotics 10 to 1000 times more than in the suspended state, and the morphology of bacteria is changed so that antibiotics are inactivated by extracellular polysaccharide or oxygen, or by biofilm formation. It slows growth and acquires tolerance.
상기 바이오필름은 포르피로모나스 진지발리스(Porphyromonas gingivalis), 아그레가티박터 액티노마이세템코미탄스(Aggregatibacter actinomycetemcomitans), 탄네렐라 포르시티아(Tannerella forsythia), 트레포네마 덴티콜라(Treponema denticola), 프레보텔라 니그레센스(Prevotella nigrescens), 유박테리움 노다툼(Eubacterium nodatum), 파르비모나스 미크라(Parvimonas micra), 아이케넬라 코로덴스(Eikenella corrodens), 캄필로박터 렉투스(Campylobacter rectus), 푸조박테리움 뉴클레아툼(Fusobacterium nucleatum), 스트렙토코쿠스 소브리누스(Streptococcus sobrinus), 스트렙토코쿠스 살리바리우스(Streptococcus salivarius), 스트렙토코쿠스 안지나서스(Streptococcus anginasus), 스트렙토코쿠스 뮤탄스(Streptococcus mutans) 및 프레보텔라 인터메디아(Prevotella intermedia)로 이루어진 군에서 선택되는 미생물에 의하여 형성된 것일 수 있으나, 이에 제한되는 것은 아니다.The biofilm is Porphyromonas gingivalis ( Porphyromonas gingivalis ), Aggregatibacter actinomycetem comitans ( Aggregatibacter actinomycetemcomitans ), Tannerella forsythia ( Tannerella forsythia ), Treponema denticola ( Treponema denticola ), Prevotella nigrescens , Eubacterium nodatum, Parvimonas micra , Eikenella corrodens, Campylobacter rectus , Fusobacterium nucleatum ( Fusobacterium nucleatum ), Streptococcus sobrinus ( Streptococcus sobrinus ), Streptococcus salivarius ( Streptococcus salivarius ), Streptococcus anginasus ( Streptococcus anginasus ), Streptococcus mutans ( Streptococcus mutans ) and Prevotella intermedia ( Prevotella intermedia ) It may be formed by a microorganism selected from the group consisting of, but is not limited thereto.
본 발명에서, "바이오필름 형성 촉진"은 바이오필름의 형성 속도를 증가시키는 것을 의미하며, 이는 상기 바이오필름 형성 미생물, 즉 구강 세균의 배양 시작 시점으로부터 단위시간 당 미생물의 생균 수 증가율 향상을 의미한다. 상기 미생물의 생균 수는 배양 이후 나타난 미생물의 집락 수를 세어 측정할 수 있으며, mL 당 생균 수(CFU/mL)로 나타낼 수 있다.In the present invention, "promoting biofilm formation" means increasing the rate of biofilm formation, which means improving the rate of increase in the number of viable cells per unit time from the start of culturing the biofilm-forming microorganisms, that is, oral bacteria. . The number of viable cells of the microorganisms may be measured by counting the number of colonies of the microorganisms appearing after culturing, and may be expressed as the number of viable cells per mL (CFU/mL).
또한, 상기 바이오필름 형성 촉진은 상기 바이오필름 형성 미생물, 즉 구강 세균을 구강 세균 배양용 조성물(배지)에서 배양하고자 할 때 이의 생육을 촉진하는 것일 수 있다. 배양 배지에서의 미생물의 생육을 촉진시키기 위하여, 본 출원의 조성물은 구강 세균 배양용 조성물(배지)에 첨가되어 이용될 수 있다.In addition, the promotion of biofilm formation may be to promote the growth of the biofilm-forming microorganisms, that is, oral bacteria, when they are to be cultured in a composition (medium) for culturing oral bacteria. In order to promote the growth of microorganisms in a culture medium, the composition of the present application may be used by being added to a composition (medium) for culturing oral bacteria.
본 발명의 다른 일 양태에 따르면, 본 발명은 황정 추출물을 유효성분으로 포함하는 구강 세균 배양용 조성물에 관한 것이다.According to another aspect of the present invention, the present invention relates to a composition for culturing oral bacteria comprising a hwangjeong extract as an active ingredient.
본 발명에서, 상기 황정 추출물에 관한 설명은 상술한 바와 동일하며, 이에 관한 설명은 상기의 설명을 원용한다.In the present invention, the description of the Hwangjeong extract is the same as described above, and the description regarding this uses the above description.
본 발명에서, 구강 세균 배양용 조성물은 바이오필름 형성 미생물, 즉 구강 세균을 배양하기 위한 목적의 조성물(배지)을 의미하며, 구강 세균의 생장에 도움을 줄 수 있는 것으로 본 출원의 기술분야에서 통상적으로 알려진 성분을 포함할 수 있다.In the present invention, the composition for culturing oral bacteria refers to a composition (medium) for the purpose of culturing biofilm-forming microorganisms, that is, oral bacteria, and can help the growth of oral bacteria, which is common in the art of the present application. It may contain ingredients known as
상기 구강 세균 배양용 조성물은 액체 또는 고체 형태일 수 있으며, 액체 형태의 배지를 한천(agar)과 혼합하여 고체화한 것일 수 있다.The oral bacterial culture composition may be in liquid or solid form, and may be solidified by mixing a liquid medium with agar.
본 발명에서, 상기 바이오필름 형성 촉진용 조성물은 상기 황정 추출물을 1 mg/mL의 농도로 포함할 수 있다.In the present invention, the composition for promoting biofilm formation may include the Hwangjeong extract at a concentration of 1 mg/mL.
상기 구강 세균 배양용 조성물은 탄소원, 질소원, 및 무기염으로 이루어진 군으로부터 선택되는 하나 이상을 더 포함할 수 있으며, 구강 세균의 배양에 최소로 요구되는 성분이나, 구강 세균의 생장에 도움을 줄 수 있는 성분이라면 제한없이 포함할 수 있다.The composition for culturing oral bacteria may further include one or more selected from the group consisting of a carbon source, a nitrogen source, and an inorganic salt, and may help the growth of oral bacteria, or a minimum component required for culturing oral bacteria. Any ingredient that is present may be included without limitation.
상기 탄소원은 글루코오스(glucose), 말토오스(maltose), 락토오스(lactose), 셀로비오스(cellobiose), 만노오스(mannose), 트레할로오스(trehalose), 프룩토오스(fructose), 멜리비오스(melibiose), 갈락토오스(galactose), 라피노오스(raffinose), 수크로오스(sucrose), 스타키오스(stachyose), 만니톨(mannitol), 아라비노오스(arabinose), 소비톨(sorbitol), 자일로오스(xylose), 에스쿨린(esculin), 람노오스(rhamnose), 살리신(salicin), 전분 등의 당류, 및/또는 구연산, 주석산, 사과산 등의 유기산, 및/또는 저분자량의 지방산일 수 있다.The carbon source is glucose, maltose, lactose, cellobiose, mannose, trehalose, fructose, melibiose, Galactose, raffinose, sucrose, stachyose, mannitol, arabinose, sorbitol, xylose, esculin It may be sugars such as esculin, rhamnose, salicin, and starch, and/or organic acids such as citric acid, tartaric acid, and malic acid, and/or low molecular weight fatty acids.
상기 질소원은 카제인, 비프 추출물(beef extract), 트립톤(tryptone), 펩톤(peptone), 소이펩톤(soypeptone), 및/또는 효모 추출물(yeast extract)일 수 있다.The nitrogen source may be casein, beef extract, tryptone, peptone, soypeptone, and/or yeast extract.
상기 무기염은 P, Na, K, Mg, S, 및/또는 Mn일 수 있으며, 상기 배양배지는 그 외 미량의 무기염을 더 포함할 수 있다. 상기 무기염은 예컨대 폴리소베이트 80, 제2인산칼륨(K2HPO4), Na-아세테이트, 시트르산 암모늄((NH4)2 citrate), 황산마그네슘(MgSO4 Х 7H2O), 황산망간(MnSO4 Х H2O) 등의 형태로 포함될 수 있고, 상기 무기염의 종류 및 함량은 배양배지의 pH, 삼투압에 따라 적절히 선택할 수 있다. 또한, 소고기 추출물, 펩톤, 효모 추출물 등 천연의 성분을 배지에 이용할 경우에는, 상기 천연 재료 내 포함되는 무기염을 고려하여, 별도의 무기염을 더 첨가하지 않거나 그 함량을 적게 설정할 수 있다.The inorganic salt may be P, Na, K, Mg, S, and/or Mn, and the culture medium may further contain trace amounts of other inorganic salts. The inorganic salt is, for example, polysorbate 80, dibasic potassium phosphate (K 2 HPO 4 ), Na-acetate, ammonium citrate ((NH 4 ) 2 citrate), magnesium sulfate (MgSO 4 Х 7H 2 O), manganese sulfate ( MnSO 4 Х H 2 O), etc., and the type and content of the inorganic salt may be appropriately selected depending on the pH and osmotic pressure of the culture medium. In addition, when natural ingredients such as beef extract, peptone, and yeast extract are used in the medium, additional inorganic salts may not be added or the content thereof may be set to be small in consideration of the inorganic salts contained in the natural materials.
상기 탄소원, 질소원, 및 무기염 성분의 함량은 상기 바이오필름 형성 촉진(구강 세균의 생육 촉진) 효능을 억제하지 않는 범위 내에서 구강 세균의 배양 목적, 목표 균 수 등에 따라 설정될 수 있다.The content of the carbon source, nitrogen source, and inorganic salt component may be set according to the purpose of culturing oral bacteria, the target number of bacteria, etc. within a range that does not inhibit the biofilm formation promoting effect (promoting the growth of oral bacteria).
상기 구강 세균 배양용 조성물은 구강 세균의 생육 촉진에 도움을 줄 수 있는 성분을 더 포함할 수 있으며, 상기 성분의 종류 및 함량은 상기 바이오필름 형성 촉진(구강 세균의 생육 촉진) 효능을 억제하지 않는 범위 내에서 구강 세균의 배양 목적, 목표 균 수 등에 따라 설정될 수 있다.The composition for culturing oral bacteria may further include a component that can help promote the growth of oral bacteria, and the type and content of the component does not inhibit the biofilm formation promoting effect (promoting the growth of oral bacteria). It can be set according to the purpose of culturing oral bacteria, the target number of bacteria, etc. within the range.
상기 구강 세균은 포르피로모나스 진지발리스(Porphyromonas gingivalis), 아그레가티박터 액티노마이세템코미탄스(Aggregatibacter actinomycetemcomitans), 탄네렐라 포르시티아(Tannerella forsythia), 트레포네마 덴티콜라(Treponema denticola), 프레보텔라 니그레센스(Prevotella nigrescens), 유박테리움 노다툼(Eubacterium nodatum), 파르비모나스 미크라(Parvimonas micra), 아이케넬라 코로덴스(Eikenella corrodens), 캄필로박터 렉투스(Campylobacter rectus), 푸조박테리움 뉴클레아툼(Fusobacterium nucleatum), 스트렙토코쿠스 소브리누스(Streptococcus sobrinus), 스트렙토코쿠스 살리바리우스(Streptococcus salivarius), 스트렙토코쿠스 안지나서스(Streptococcus anginasus), 스트렙토코쿠스 뮤탄스(Streptococcus mutans) 및 프레보텔라 인터메디아(Prevotella intermedia)로 이루어진 군에서 선택되는 것일 수 있으나, 이에 제한되는 것은 아니다.The oral bacteria are Porphyromonas gingivalis , Aggregatibacter actinomycetemcomitans , Tannerella forsythia , Treponema denticola , Prevotella nigrescens , Eubacterium nodatum, Parvimonas micra , Eikenella corrodens, Campylobacter rectus , Fusobacterium nucleatum ( Fusobacterium nucleatum ), Streptococcus sobrinus ( Streptococcus sobrinus ), Streptococcus salivarius ( Streptococcus salivarius ), Streptococcus anginasus ( Streptococcus anginasus ), Streptococcus mutans ( Streptococcus mutans ) and Prevotella intermedia ( Prevotella intermedia ) It may be selected from the group consisting of, but is not limited thereto.
본 발명은 황정 추출물을 유효성분으로 포함하는 바이오필름 형성 촉진용 조성물에 관한 것으로, 본 발명에 따른 황정 추출물을 사용하는 경우 구강용 혐기성 세균의 in vitro 세포실험에 있어 매우 경제적이며, 동물실험에 사용되는 노력과 비용을 절감할 수 있는 바, 각종 구강용품, 구강질환 치료제 등의 개발에 유용하게 사용될 수 있다.The present invention relates to a composition for promoting biofilm formation containing Hwangjeong extract as an active ingredient. When using the Hwangjeong extract according to the present invention, it is very economical for in vitro cell experiments of oral anaerobic bacteria and used for animal experiments Since it can reduce the effort and cost, it can be usefully used in the development of various oral products and oral disease treatments.
도 1은 본 발명의 일 실시예에 따른 본 발명의 황정 추출물의 바이오필름 형성 촉진능 평가 결과를 나타낸다.
도 2는 본 발명의 일 실시예에 따른 본 발명의 황정 추출물의 바이오필름 형성 촉진능 평가 결과를 나타낸다.Figure 1 shows the biofilm formation promoting ability evaluation results of the Hwangjeong extract of the present invention according to an embodiment of the present invention.
Figure 2 shows the biofilm formation promoting ability evaluation results of the Hwangjeong extract of the present invention according to an embodiment of the present invention.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail through examples. These examples are only for explaining the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention. .
모든 실험의 결과는 Mean±Standard error로 표기하였고, 실험자료의 통계 분석은 Student's t-test로 하였으며, p 값이 0.001 미만일 때 통계적으로 유의한 것으로 판단하였다.The results of all experiments were expressed as Mean±Standard error, and the statistical analysis of the experimental data was performed with Student's t-test, and it was judged to be statistically significant when the p value was less than 0.001.
실험예. 황정 추출물의 바이오필름 형성 촉진 효과 평가experimental example. Evaluation of biofilm formation promoting effect of Hwangjeong extract
실험에 사용된 황정(Polygonati Rhizoma) 열수 추출물(21.26 mg/mL)은 한국 식물 추출물 은행(Korea Plant Extract Bank, KPEB)으로부터 제공받았으며, 황정 추출물의 분양번호는 CW04-096이다.Hwangjeong ( Polygonati Rhizoma ) hot water extract (21.26 mg/mL) used in the experiment was provided by Korea Plant Extract Bank (KPEB), and the distribution number of Hwangjeong extract is CW04-096.
티타늄 디스크(지름 10 mm, Dentium) 위에 여과한 타액(saliva)을 200 μL씩 뿌려준 후 ∞ 모양으로 살살 흔들어주었다. 4 시간 동안 37 ℃에서 인큐베이션한 후, 타액을 제거하였다.After spraying 200 μL of filtered saliva on a titanium disk (10 mm in diameter, Dentium), it was gently shaken in an ∞ shape. After incubation at 37° C. for 4 hours, saliva was removed.
P. gingivalis(ATCC 33277, KCOM) 500 μL를 BHI 배지(BHI, Hemin 5 μg/mL, 및 Vitamin K1 1μg/mL) 9.5 mL에 넣고 24 시간 동안 37 ℃에서 배양한 후, 배양액을 1.5 mL e-tube에 1 mL씩 담고 12,000 rpm에서 3 분 동안 원심분리하였다. 상층액을 버린 후, BHI 배지 1 mL를 첨가하여 펠릿(pellet)을 풀어주었다. 그 다음, 20 μL를 따서 BHI 배지 380 μL에 1/20로 희석하였다. 희석한 배양액 200 μL를 96-웰 플레이트에 넣고, OD600을 측정하였다. 측정된 OD600 값을 바탕으로, 1Х108 CFU/mL로 하기의 방법을 이용하여 P. gingivalis의 투입 부피(input volume)를 계산하였다.Add 500 μL of P. gingivalis (ATCC 33277, KCOM) to 9.5 mL of BHI medium (BHI, Hemin 5 μg/mL, and Vitamin K1 1 μg/mL) and incubate at 37 °C for 24 hours. Each 1 mL was put into a tube and centrifuged at 12,000 rpm for 3 minutes. After discarding the supernatant, 1 mL of BHI medium was added to release the pellet. Then, 20 μL was taken and diluted 1/20 in 380 μL of BHI medium. 200 μL of the diluted culture medium was put into a 96-well plate, and OD 600 was measured. Based on the measured OD 600 value, the input volume of P. gingivalis was calculated at 1Х10 8 CFU/mL using the following method.
[1 mL 안에 들어 있는 P. gingivalis의 총 CFU, 원액][Total CFU of P. gingivalis in 1 mL, stock solution]
= {7156.4(0.229; OD 희석 값 - 0.065; OD 배지) - 20.258= {7156.4 (0.229; OD dilution value - 0.065; OD medium) - 20.258
= (1153.3916Х106 CFU/mL) Х 20= (1153.3916Х10 6 CFU/mL) Х 20
= 23067.832Х106 CFU/mL= 23067.832Х10 6 CFU/mL
= 230.67832Х108 CFU/mL= 230.67832Х10 8 CFU/mL
이때, 전체 부피가 4 mL(4 개의 디스크에 1 mL씩 접종)라 할 때, 투입 부피(하기 X)는,At this time, when the total volume is 4 mL (1 mL inoculated on 4 disks), the input volume (X below) is,
X μL = (1Х108 CFU/mL)/(230.67832Х108 CFU/mL) Х 4 mLX μL = (1Х10 8 CFU/mL)/(230.67832Х10 8 CFU/mL) Х 4 mL
= (1Х108 CFU/mL)/(230.67832Х108 CFU/mL) Х 4,000 μL= (1Х10 8 CFU/mL)/(230.67832Х10 8 CFU/mL) Х 4,000 μL
= 17.34013436= 17.34013436
= 17.34 μL= 17.34 µL
또한, 하기 계산식 1을 사용하여 황정 추출물의 투입 부피를 계산하였다.In addition, the input volume of the Hwangjeong extract was calculated using Equation 1 below.
[계산식 1][Calculation 1]
BHI 배지 4 mL에서, 상기에서 계산된 P. gingivlais의 투입 부피인 17.34 μL 및 황정 추출물의 투입 부피인 11.76 μL(1 mg/mL)를 각각 제거하였다. 각 부피가 제거된 배지에 상기에서 준비된 티타늄 디스크, P. gingivlais 배양액 17.34 μL 및 황정 추출물(1 mg/mL) 11.76 μL를 각각 첨가한 뒤, 볼텍싱(vortexing)을 진행하였다. 그 다음, 24-웰 플레이트의 각 웰에 1 mL씩 넣고 ∞ 모양으로 살살 흔들어주었다. 37 ℃의 혐기성 챔버(anaerobic chamber, Whitley DG 250 Workstation 230v/50Hz, 80% N2, 10% CO2 및 10% H2 and N2 100%)에서 72 시간 동안 인큐베이션하였다.In 4 mL of BHI medium, 17.34 μL, the input volume of P. gingivlais calculated above, and 11.76 μL (1 mg/mL), the input volume of Hwangjeong extract, were respectively removed. The titanium disc prepared above, 17.34 μL of P. gingivlais culture medium, and 11.76 μL of Hwangjeong extract (1 mg/mL) were added to the medium from which each volume was removed, respectively, followed by vortexing. Then, 1 mL was added to each well of the 24-well plate and gently shaken in an ∞ pattern. It was incubated for 72 hours in an anaerobic chamber (anaerobic chamber, Whitley DG 250 Workstation 230v/50Hz, 80% N 2 , 10% CO 2 and 10% H 2 and
각 웰 내 배지를 흡인(suction)하고 DPBS로 2회 세척하였다. 차광하여 실온에서 10 분 동안 크리스탈 바이올렛(Crystal violet)으로 염색하였다. DPBS로 3회 세척하였다. 티타늄 디스크를 새로운 플레이트에 이동시킨 후 탈염색 버퍼(Destaining buffer)로 크리스탈 바이올렛을 녹이고, 24-웰 플레이트의 각 웰에 넣은 후 OD595를 측정하였다.Media in each well was aspirated and washed twice with DPBS. It was stained with crystal violet for 10 minutes at room temperature under light blocking. Washed 3 times with DPBS. After moving the titanium disk to a new plate, crystal violet was dissolved in a destaining buffer, put into each well of a 24-well plate, and OD 595 was measured.
도 1 및 2에서 확인할 수 있듯이, 1mg/mL의 황정 추출물은 P. gingivalis의 바이오필름 형성을 촉진하였고, 이를 통해 잇몸 원인균 배양에 소모되는 시간과 비용을 절약하고, 안정적인 실험 환경을 조성할 수 있게 되었다. 이를 통해, 구강 건강 제품의 개발이 촉진될 수 있을 것으로 기대된다.As can be seen in Figures 1 and 2, 1mg / mL of Hwangjeong extract promotes the formation of a biofilm of P. gingivalis , thereby saving time and money spent on culturing gum causative bacteria, and creating a stable experimental environment It became. Through this, it is expected that the development of oral health products can be promoted.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210130032A KR20230046711A (en) | 2021-09-30 | 2021-09-30 | COMPOSITION FOR PROMOTING BIOFILM FORMATION COMPRISING EXTRACT OF Polygonati Rhizoma |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210130032A KR20230046711A (en) | 2021-09-30 | 2021-09-30 | COMPOSITION FOR PROMOTING BIOFILM FORMATION COMPRISING EXTRACT OF Polygonati Rhizoma |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20230046711A true KR20230046711A (en) | 2023-04-06 |
Family
ID=85917847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210130032A KR20230046711A (en) | 2021-09-30 | 2021-09-30 | COMPOSITION FOR PROMOTING BIOFILM FORMATION COMPRISING EXTRACT OF Polygonati Rhizoma |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20230046711A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101908411B1 (en) | 2017-06-20 | 2018-10-17 | 대한민국 | Novel domestic-type methicillin-resistant Staphylococcus aureus strains and screening method for inhibiting biofilm formation |
-
2021
- 2021-09-30 KR KR1020210130032A patent/KR20230046711A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101908411B1 (en) | 2017-06-20 | 2018-10-17 | 대한민국 | Novel domestic-type methicillin-resistant Staphylococcus aureus strains and screening method for inhibiting biofilm formation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lee et al. | Inhibitory effect of Aralia continentalis on the cariogenic properties of Streptococcus mutans | |
Jeong et al. | Kaurenoic acid from Aralia continentalis inhibits biofilm formation of Streptococcus mutans | |
Yu et al. | Saussurea lappa inhibits the growth, acid production, adhesion, and water-insoluble glucan synthesis of Streptococcus mutans | |
KR100663284B1 (en) | The fruits extracts of dendropanax morbifera leveille having the excellent biological activity | |
Fteita et al. | Quorum sensing molecules regulate epithelial cytokine response and biofilm-related virulence of three Prevotella species | |
EP3714701B1 (en) | Composition for type iv allergy | |
Esawy et al. | Evaluated bioactive component extracted from Punica granatum peel and its Ag NPs forms as mouthwash against dental plaque | |
MX2012010988A (en) | Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells. | |
KR20230046711A (en) | COMPOSITION FOR PROMOTING BIOFILM FORMATION COMPRISING EXTRACT OF Polygonati Rhizoma | |
Karim et al. | LuxS affects biofilm maturation and detachment of the periodontopathogenic bacterium Eikenella corrodens | |
Fukui et al. | Induction of shikonin biosynthesis by endogenous polysaccharides in Lithospermum erythrorhizon cell suspension cultures | |
Amarasinghe et al. | Transcriptional and translational analysis of biofilm determinants of Aggregatibacter actinomycetemcomitans in response to environmental perturbation | |
KR20230046681A (en) | COMPOSITION FOR PROMOTING BIOFILM FORMATION COMPRISING EXTRACT OF Phellodendri Cortex | |
KR20230046776A (en) | Composition for promoting biofilm formation comprising extract of machili thunbergi cortex | |
KR20230046649A (en) | Composition for promoting biofilm formation comprising extract of cartami semen | |
KR20230046743A (en) | COMPOSITION FOR PROMOTING BIOFILM FORMATION COMPRISING EXTRACT OF Astragali Radix | |
KR20230046680A (en) | COMPOSITION FOR PROMOTING BIOFILM FORMATION COMPRISING EXTRACT OF Rosa rugosa Root | |
KR20230046787A (en) | Composition for promoting biofilm formation comprising extract of biotae orientalis folium | |
KR20230046622A (en) | Composition for promoting biofilm formation comprising extract of pini pollen | |
KR20230046693A (en) | Composition for promoting biofilm formation comprising extract of rosa laevigata | |
Eltigani et al. | Argeloside I inhibits the pathogenicity of Porphyromonas gingivalis TDC60 | |
Hindi et al. | Evaluation of antibacterial activity: anti adherence, anti biofilm and anti swarming of the aquatic extract of black raisins and vinegar of black raisins in Hilla City, Iraq | |
Takatani et al. | Identification of a novel carotenoid, 2′-isopentenylsaproxanthin, by Jejuia pallidilutea strain 11shimoA1 and its increased production under alkaline condition | |
KR20050022276A (en) | Extract of plant dendrobii caulis and preparing process thereof | |
KR102485257B1 (en) | Composition comprising lactic acid bacteria derived from camellia japonica for caring damages of skin cells by microdust |